Clinical Trials

21/013 VitAL

The Ventilation Imaging for Thoracic Lung cancer radiation therapy (VITaL) trial
Recruitment target:
130
(Final recruitment number)
Status:
In Start-up
(Seeking funding)

Lead Researchers:

Professor Paul Keall, The University of Sydney

Summary:

Radiation therapy (RT) is indicated for 77% of lung cancer patients. A common adverse event, affecting at least 20% of patients, is radiation-induced lung injury. To minimise radiation-induced lung injury, Professor Keall’s team has invented and pioneered ventilation imaging based on computed tomography (CT) which has been developed into a medical device (CIA). This medical device uses CT scans routinely acquired for planning RT to compute a CT ventilation map showing high functioning and low functioning lung regions.

VitAL aims to investigate whether the use of CIA can be used to direct radiation away from the healthy, high functioning regions towards the low functioning regions, thereby reducing toxicity and improving the patient’s quality of life.

Clinical trial design:

A double-blind, prospective, randomised phase III clinical trial.

Indication:

Stage I-III non-small lung cancer (NSLC) patients to be treated with curative intent with external beam radiotherapy (RT).

Intervention:

Patients will be randomised between treatment with or without a plan that deliberately spares the high functioning lung, as measured by CT ventilation imaging, from high doses of radiation.

More Clinical Trials

In Start-up:

In Start-up
The ADOPT-Lung study will examine disease free status (DFS) following 12 months of adjuvant durvalumab in addition to neoadjuvant chemotherapy and durvalumab in NSCLC patients who do not achieve a complete pathological response following surgery. ‘Operable’ patients will be given 3-4 cycles of neoadjuvant durvalumab and chemotherapy every 3 weeks, and provided the tumour is satisfactorily removed by surgery (R0 or R1), the patients will be randomised to 12 months of durvalumab given every 4 weeks, or observation. Participants will have CT scans every 12 weeks in the first year, and every 6 months in years 2 and 3. Blood will be collected at the scan visit to measure correlation of DFS with ctDNA clearance.